Long-term Outcomes of Psychological Treatment for Posttraumatic Stress Disorder: A Systematic Review and Meta-Analysis - Corrigendum

Weber, Maxi; Schumacher, Sarah; Hannig, Wiebke; Barth, Jürgen; Lotzin, Annett; Schäfer, Ingo; Ehring, Thomas; Kleim, Birgit

doi:10.1017/s0033291721003214

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although these approaches are described as “gold standard,” systematic reviews and meta-analyses reveal roughly similar levels of efficacy and acceptability among these and other psychotherapy strategies to treat PTSD [ 222 , 223 ]. Initial outcomes appear strong: One meta-analysis reported that patients treated using PE have better outcomes on post-treatment PTSD measures than individuals treated using control conditions [ 180 ].…”

Section: Ptsd Overviewmentioning

confidence: 99%

“…In another meta-analysis of psychotherapies for PTSD with a minimum of 12 months follow-up, trauma-focused therapy (TFT), CBT, and EMDR were associated with large effect sizes for pretest compared with follow-up. However, only small effect sizes were found when compared with non-directive control groups that included treatment as usual (TAU), social counseling, educational groups, and Present-Centered Therapy (PCT) [ 223 ].…”

Section: Ptsd Overviewmentioning

confidence: 99%

See 1 more Smart Citation

The Psychedelic Future of Post-Traumatic Stress Disorder Treatment

Zaretsky,

Jagodnik,

Barsic

et al. 2024

View full text Add to dashboard Cite

Post-traumatic stress disorder (PTSD) is a mental health condition that can occur following exposure to a traumatic experience. An estimated 12 million U.S. adults are presently affected by this disorder. Current treatments include psychological therapies (e.g., exposure-based interventions) and pharmacological treatments (e.g., selective serotonin reuptake inhibitors (SSRIs)). However, a significant proportion of patients receiving standard-of-care therapies for PTSD remain symptomatic, and new approaches for this and other trauma-related mental health conditions are greatly needed. Psychedelic compounds that alter cognition, perception, and mood are currently being examined for their efficacy in treating PTSD despite their current status as Drug Enforcement Administration (DEA)- scheduled substances. Initial clinical trials have demonstrated the potential value of psychedelicassisted therapy to treat PTSD and other psychiatric disorders. In this comprehensive review, we summarize the state of the science of PTSD clinical care, including current treatments and their shortcomings. We review clinical studies of psychedelic interventions to treat PTSD, trauma-related disorders, and common comorbidities. The classic psychedelics psilocybin, lysergic acid diethylamide (LSD), and N,N-dimethyltryptamine (DMT) and DMT-containing ayahuasca, as well as the entactogen 3,4-methylenedioxymethamphetamine (MDMA) and the dissociative anesthetic ketamine, are reviewed. For each drug, we present the history of use, psychological and somatic effects, pharmacology, and safety profile. The rationale and proposed mechanisms for use in treating PTSD and traumarelated disorders are discussed. This review concludes with an in-depth consideration of future directions for the psychiatric applications of psychedelics to maximize therapeutic benefit and minimize risk in individuals and communities impacted by trauma-related conditions.

show abstract

Section: Ptsd Overviewmentioning

confidence: 99%

Section: Ptsd Overviewmentioning

confidence: 99%